Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study of Pravastatin vs Placebo as Primary Prevention of Severe Subcutaneous Breast Fibrosis in Hyper-radiosensitive Identified Patients With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women ≥ 18 years old (no age limit)~2. Conservative breast cancer surgery~3. High risk level of breast fibrosis identified by the centralized NovaGray RILA Breast® test~4. Invasive carcinoma : pT1-T2; pN0 (negative sentinel nodes or axillary nodes dissection) and/or Ductal in situ carcinoma~5. Negative surgical margins~6. Indication of whole breast irradiation only (with or without boost to tumor bed according to physician discretion)~7. Only 3D-conformal RT will be allowed~8. Blood sample allowing pravastatin use : serum creatinine ≤ 130 µmol/l; ASAT and ALAT≤ 2N; total bilirubin ≤ 1.5N; CK MM levels \< 3 x ULN for women ≥ 70 years (at least 15 days before randomization).~9. Negative pregnancy test in women of childbearing potential (β-HCG dosage ≤ 7 days prior to randomization), an adequate contraception should be used from the beginning of the study to 4 weeks after last treatment dose. The women not of reproductive potential are female patients who are postmenopausal (with a minimum of one year without menstruation and without alternative medical cause) or permanently sterilized: e.g., tubal occlusion, hysterectomy, bilateral salpingectomy).~10. Must be geographically accessible for follow-up~11. Written and dated informed consent~12. Affiliated to the French national social security system~Exclusion Criteria:~1. Current treatment by : statin, fibrate, ciclosporin, systemic fusidic acid, long-term treatment by corticoids~2. History of muscular dystrophy diseases or chronic and/or hereditary muscular diseases~3. Patients with distant metastases~4. Indications of node irradiation (axillar or supraclavicular or mammary chain)~5. T3-4 or N1-3 breast cancer~6. Patients who underwent radical mastectomy~7. Neoadjuvant systemic therapy (chemotherapy, hormonotherapy, targeted therapies)~8. Patients with previous or concomitant other (not breast cancer) malignancy within the past 5 years EXCEPT adequately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix. Patients who have had a previous other malignancy must have been disease free for at least five years~9. Patients with other non-malignant systemic diseases (cardiovascular, renal, hepatic, lung embolism, infection etc.) which would disrupt extended follow-up~10. Untreated hypothyroidism~11. Known positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAG) or hepatitis C virus (HCV) antibody~12. Pregnant or breastfeeding women~13. women of childbearing potential who are unwilling to employ adequate contraception, from the beginning of the study to 4 weeks after last treatment dose~14. Known hypersensitivity to pravastatine, or any constituent of the product.~15. Patient with alcohol misuse.~16. Legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent or to terminate the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EXPERIMENTAL GROUP (Type: EXPERIMENTAL): RADIOTHERAPY + PRAVASTATIN
- CONTROL GROUP (Type: PLACEBO_COMPARATOR): RADIOTHERAPY + PLACEBO

Based on this trial design, predict the completion outcome and termination type (if applicable).